drugset / Trial / NCT07682376
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Active not recruiting
96 enrolled
Harbin Medical University
Henan Cancer Hospital · collabPeking Union Medical College Hospital · collabShanxi Province Cancer Hospital · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy and safety of neoadjuvant low-dose radiotherapy combined with Retlirafusp alfa and chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma.
Timeline
- Start
- 2026-06-10
- Primary completion
- 2028-05-30
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 30 mg/kg | — |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | 1800 mg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | — |